MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q1
hinzugefügt 01.05.2025
Blueprint Medicines Corporation Anteile 2011-2026 | BPMC
Anteile Jährlich Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.9 M | 60.6 M | 59.6 M | 58.5 M | 54.5 M | 47.8 M | 43.9 M | 37.8 M | 27.5 M | 18.2 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 62.9 M | 18.2 M | 47.1 M |
Anteile Vierteljährlich Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.1 M | 63.7 M | 63.4 M | 62.9 M | 61.6 M | 61.1 M | 60.7 M | 60.5 M | 60.1 M | 60 M | 59.8 M | 59.6 M | 59.3 M | 59.1 M | 58.6 M | 58.4 M | 58 M | 57.8 M | 55.2 M | 54.2 M | 52.7 M | 49.3 M | 48.9 M | 48.8 M | 44.1 M | 44 M | 43.9 M | 43.9 M | 43.7 M | 43.6 M | 39.1 M | 38.8 M | 33.2 M | 33.1 M | 27.3 M | 27.2 M | 27.1 M | 27.1 M | 26.8 M | 17.1 M | 1.68 M | 1.63 M | 1.45 M | 1.37 M | 1.28 M | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 64.1 M | 1.28 M | 43.7 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
299 M | $ 3.65 | -1.75 % | $ 1.09 B |  Canada |
 |
ADMA Biologics
ADMA
|
238 M | $ 16.5 | 0.73 % | $ 3.93 B |  USA |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
126 M | $ 19.78 | -1.89 % | $ 2.5 B | USA |
 |
Aptorum Group Limited
APM
|
5.45 M | $ 0.82 | 4.04 % | $ 4.47 M |  China |
 |
Graybug Vision
GRAY
|
15 M | - | -11.23 % | $ 9.65 M | USA |
 |
Axsome Therapeutics
AXSM
|
49.7 M | $ 164.62 | 0.34 % | $ 8.19 B | USA |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
BioLineRx Ltd.
BLRX
|
663 M | $ 2.93 | 4.27 % | $ 908 M |  Israel |
 |
Athersys
ATHX
|
224 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
32.7 M | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
192 M | $ 59.93 | 2.39 % | $ 11.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 8.51 | -0.53 % | $ 1.39 B | Britain |
 |
Cabaletta Bio
CABA
|
1.17 M | $ 3.37 | 3.66 % | $ 3.94 M | USA |
 |
BridgeBio Pharma
BBIO
|
192 M | $ 65.44 | 1.41 % | $ 12.5 B | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
63.2 M | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Codexis
CDXS
|
73.4 M | $ 1.04 | 6.29 % | $ 76.3 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
39.7 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
8.33 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
116 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
94.2 M | $ 1.75 | 5.76 % | $ 165 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
115 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
2.9 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
22.3 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
22.3 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
85.1 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
26.8 M | $ 26.27 | 1.66 % | $ 703 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | USA |
 |
Certara
CERT
|
160 M | $ 7.3 | 0.83 % | $ 1.17 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
6.73 M | $ 0.82 | 10.93 % | $ 5.52 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
43.3 M | - | - | $ 105 M | USA |